Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Flupentixol→

Flupentixol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2709-56-0
Molecular formula
C23H25F3N2OS
Molecular weight
434.5 g/mol
Drug class
Thioxanthene antipsychoticdopamine D2 receptor antagonist
Mechanism of action
Antagonises central dopamine D2 receptors and also interacts with other monoamine receptors, reducing dopaminergic signalling associated with psychosis. Low-dose and depot formulations have different clinical uses and duration.
Indications / reported uses
  • Treatment of schizophrenia and other psychotic disorders with oral or depot formulations in countries where authorised
  • Low-dose oral flupentixol has been used for depressive or anxiety symptoms in some jurisdictions, but these indications are not universal and should be assigned only to the specific authorised product

Sources: NHS — Flupentixol · NLM MeSH — Flupentixol · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Thioxanthene antipsychotic; dopamine D2 receptor antagonist

Mechanism of action

Antagonises central dopamine D2 receptors and also interacts with other monoamine receptors, reducing dopaminergic signalling associated with psychosis. Low-dose and depot formulations have different clinical uses and duration.

General use cases

  • Treatment of schizophrenia and other psychotic disorders with oral or depot formulations in countries where authorised
  • Low-dose oral flupentixol has been used for depressive or anxiety symptoms in some jurisdictions, but these indications are not universal and should be assigned only to the specific authorised product

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Flupentixol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Flupentixol Permitted Daily Exposure (PDE) report (the Flupentixol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Flupentixol Occupational Exposure Limit (OEL) report (the Flupentixol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.